1. Evaluation of new chlorhexidine- and cetylpyridinium chloride-based mouthrinse formulations adjunctive to scaling and root planing: pilot study.
- Author
-
García‐Gargallo, M, Zurlohe, M, Montero, E, Alonso, B, Serrano, J, Sanz, M, and Herrera, D
- Subjects
CHRONIC disease treatment ,DENTAL plaque ,ORAL microbiology ,PERIODONTITIS treatment ,ANALYSIS of variance ,CHI-squared test ,CHLORHEXIDINE ,DENTAL scaling ,DENTAL schools ,INTERVIEWING ,MOUTHWASHES ,PROBABILITY theory ,PYRIDINE ,QUESTIONNAIRES ,RESEARCH funding ,TOOTH root planing ,PILOT projects ,DATA analysis ,RANDOMIZED controlled trials ,VISUAL analog scale ,BLIND experiment ,DATA analysis software ,DESCRIPTIVE statistics ,KRUSKAL-Wallis Test ,PREVENTION - Abstract
Objective To compare the effect of two newly formulated chlorhexidine ( CHX) and cetylpyridinium chloride ( CPC) mouthrinses after scaling and root planing ( SRP) in terms of clinical, microbiological, patient-based variables and adverse events, with a positive control with the same active components, already marketed and tested. Methods A pilot, randomized clinical trial, double-blind, parallel design with 1-month follow-up was conducted. Chronic periodontitis patients requiring non-surgical periodontal therapy were enrolled and randomly assigned to: (i) SRP and test-1 (new reformulation: 0.12% CHX and 0.05% CPC); (ii) SRP and test-2 (new formulation: 0.03% CHX and 0.05% CPC); or (iii) SRP and positive control (commercial product: 0.12% CHX and 0.05% CPC). All variables were evaluated at baseline and 1 month after SRP. Quantitative variables were compared by means of anova or Kruskal-Wallis test and qualitative variables by chi-square or McNemar tests. Results Thirty patients (10 per group) were included. After 1 month, there were significant differences among groups in plaque levels ( P = 0.016) as test-1 showed less sites with plaque than test-2 (31.15% [standard error- SE 2.21%] versus 49.39% [ SE 4.60%), respectively). No significant differences were found for global patient perception of the product or in adverse effects. Test groups showed better results in levels and proportions ( P = 0.022) of Capnocytophaga spp. Conclusions Within the limitations of this pilot study, it can be concluded that the newly formulated 0.12% CHX and 0.05% CPC mouthrinse showed larger plaque level reductions, without showing more adverse effects, when compared to the other two mouthrinses, after SRP. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF